Neuronetics Q1 revenue $15.5M (+10% YoY); narrows FY revenue guidance to $68-73M

Neuronetics, Inc.

2023-Q1 EPS reported -$0.38 revenue$15,540,000

Net loss of $(10.5)M or $(0.38)/share vs $(10.8)M or $(0.41)/share in Q1 2022.
U.S. treatment session revenue rose 12% to $10.6M; shipped 49 NeuroStar systems.
Full-year 2023 revenue guidance set at $68-73M; Q2 2023 revenue expected $17-18M.
Amended SLR credit facility provides up to $60M at SOFR+5.65%, interest-only until March 2026.
United Healthcare and BCBS of Mississippi updated policies to allow NPPs to prescribe TMS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neuronetics, Inc. reported the three months ended March 31, 2023 results: revenue $15.5 million, net income $(10.5) million, EPS $(0.38) per share.

Period: the three months ended March 31, 2023
Revenue: $15.5 million
Net income: $(10.5) million
EPS: $(0.38) per share
Result: reported results

Exact text from the filing

therapies in the world, today announced its financial and operating results for the first quarter of 2023. First Quarter 2023 Highlights ● First quarter 2023 revenue of $15.5 million, an increase of 10% over the first quarter of 2022 ● U.S. treatment session revenue increased 12% over the first quarter of 2022 ● Shipped 49 systems continuing our capital

View on SEC.gov

Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008665

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.